Lombard Odier Asset Management (Switzerland) Sa Rubius Therapeutics, Inc. Transaction History

Lombard Odier Asset Management (Switzerland) Sa

$1.14 Billion
Q3 2024

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.79 - $5.98 $205,335 - $1.55 Million	-259,918 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$4.25 - $10.4 $32,873 - $80,444	-7,735 Reduced 2.89%	259,918 $1.43 Million
Q4 2021 Feb 14, 2022	BUY	$9.68 - $17.74 $219,155 - $401,633	22,640 Added 9.24%	267,653 $2.59 Million
Q3 2021 Nov 12, 2021	BUY	$17.6 - $25.91 $400,329 - $589,348	22,746 Added 10.23%	245,013 $4.38 Million
Q2 2021 Aug 13, 2021	BUY	$22.26 - $28.43 $1.3 Million - $1.66 Million	58,265 Added 35.53%	222,267 $5.43 Million
Q1 2021 May 17, 2021	BUY	$8.02 - $32.01 $1.32 Million - $5.25 Million	164,002 New	164,002 $4.35 Million

Others Institutions Holding RUBY

# of Institutions

Shares Held

325

Call Options Held

Put Options Held

American Portfolios Advisors Holbrook, NY

325
Shares

$0
0.0% of portfolio
Concourse Financial Group Securities, Inc. Birmingham, AL

0
Shares

$0
0.0% of portfolio

View Full List

About Rubius Therapeutics, Inc.

Ticker RUBY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,357,000
Description
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatmen...

More about RUBY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lombard Odier Asset Management (Switzerland) Sa, based on Form 13F filings with the SEC.

News

Stay updated on Lombard Odier Asset Management (Switzerland) Sa with notifications on news.

Account